$AVTX insider trading
Over the last 12 months, Avalo Therapeutics insiders reported no purchases and 20 sales totaling $8.1M across SEC Form 4 filings. 90% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $8.1M 20 events
- Events · 12m
- 20 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 90% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 679 | $20 | $14K | -1.3% | plan |
| Aug 18, 2026 | Sullivan Christopher RyanChief Financial Officer · O | ▼ Sale | 72,725 | $19.94 | $1.5M | -64.6% | plan · 3 tranches |
| Aug 17, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 1,000 | $20 | $20K | -1.9% | plan |
| Aug 11, 2026 | Riley JenniferChief Strategy Officer · O | ▼ Sale | 2,655 | $19.59 | $52K | -6.7% | — |
| Aug 10, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 679 | $20 | $14K | -1.3% | plan |
| Jul 27, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 1,000 | $20 | $20K | -1.9% | plan |
| Jun 30, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 4,654 | $20 | $93K | -8.2% | plan |
| Jun 23, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 1,450 | $18 | $26K | -2.7% | plan |
| May 28, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 679 | $16 | $11K | -1.4% | plan |
| May 7, 2026 | Sullivan Christopher RyanChief Financial Officer · O | ▼ Sale | 18,606 | $24.12 | $449K | -97.8% | plan |
| May 6, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 108,234 | $20.61 | $2.2M | -96.8% | plan · 6 tranches |
| May 6, 2026 | Sullivan Christopher RyanChief Financial Officer · O | ▼ Sale | 47,000 | $20.19 | $949K | -99.1% | plan · 5 tranches |
| May 6, 2026 | Chan MitchellD | ▼ Sale | 3,167 | $22.88 | $72K | -50% | plan |
| May 6, 2026 | VARKI PAULChief Legal Officer · O | ▼ Sale | 75,063 | $20.17 | $1.5M | -95.4% | plan · 5 tranches |
| Apr 30, 2026 | Sullivan Christopher RyanChief Financial Officer · O | ▼ Sale | 16,915 | $13.16 | $223K | -97.6% | plan · 2 tranches |
| Apr 6, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 3,970 | $18.01 | $72K | -52.3% | plan |
| Apr 2, 2026 | Sullivan Christopher RyanChief Financial Officer · O | ▼ Sale | 15,959 | $16.96 | $271K | -47.9% | plan · 4 tranches |
| Apr 1, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 679 | $16 | $11K | -15.8% | plan |
| Mar 16, 2026 | Doyle MittieChief Medical Officer · O | ▼ Sale | 25,492 | $16.15 | $412K | -87.6% | plan |
| Nov 14, 2025 | Goldman JonathanD | ▼ Sale | 11,367 | $14.33 | $163K | -100% | 2 tranches |
Every $AVTX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Avalo Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AVTX feed.